GERMAN CANCER RESEARCH CENTER
IN THE HELMHOLTZ ASSOCIATION

50 Years – Research for
A Life Without Cancer

Office of
Technology Transfer

TECHNOLOGY OFFER

July 18

Title	**Treatments of Non-Alcoholic Steatohepatitis (NASH)**	
P-No.	**1305**	
Inventor(s)	**Matthias**	**Heikenwälder**
	Achim	**Weber**
	Thomas	**Zender**
TTO Representative	**Dr. Dirk Kuck**	
	Project Manager	**Technology Transfer Office**
	d.kuck@dkfz.de	**+49 6221 42 29 45**
	German Cancer Research Center (DKFZ)	
	Im Neuenheimer Feld 280	
	69120 Heidelberg	
	Germany	
Technology Summary	Changes in lifestyle over the last few decades such as high caloric intake (e.g. through high-fat, high-fructose and high-glucose diets) combined with a sedentary lifestyle have increased the incidence of overweight and metabolic syndrome, which is characterized by abdominal obesity, insulin resistance, hypertonia and dyslipidemia. The latest WHO cancer report predicts a doubling in cancer incidence within the next two decades, the great majority of which will be attributable to modifiable risk factors such as high caloric intake, smoking and a sedentary lifestyle. The liver, which is the most important metabolic organ in the body, is greatly affected by a chronic state of hypercaloric uptake, overweight, sedentary lifestyle and the resulting pathology (metabolic syndrome). Non-alcoholic fatty liver disease (NAFLD), comprising several liver diseases including NAFL and NASH, which is the most frequent liver disease world-wide, is a clinical manifestation of overweight and metabolic syndrome. The prevalence of NAFL is increasing globally. Currently, 90 million Americans and 40 million Europeans suffer from NAFLD. A significant number of NAFL patients develop non-alcoholic steatohepatitis (NASH), fibrosis and, subsequently, hepatocellular carcinoma (HCC).	
Detailed Technology De-	Compounds were identified that target thrombocyte activity or aggregation	

scription	capacity through cellular components for the treatment of diseases associated with non-alcoholic fatty liver disease (NAFLD). These compounds are effective for treating non-alcoholic steatohepatitis (NASH), an advanced stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and hepatocellular carcinoma (HCC). Also provided are methods for screening for new NASH therapeutics.
Tags or Keywords	**NASH, NAFLD, HCC, treatment**
Technology Benefit	Treatment of non-alcoholic steatohepatitis (NASH), an advanced stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and hepatocellular carcinoma (HCC).
Technology Applications	Pharmaceutical composition
Technology page URL	**https://www.dkfz.de/en/techtrans/availabletechnologies/index.html**
TTO home page URL	
Link	**https://www.dkfz.de/en/techtrans/**
Thumbnail images	

Patents

Patent Number	**Title**	**Link**
WO 2018/002155	**Treatments of Non-Alcoholic Steatohepatitis (NASH)**	
Issue Date	**Publication Date**	**Application Date**
	04.01.2018	**28.06.2016**

Additional Fields